Page 261 - 2021_03-Haematologica-web

Letters to the Editor
Contributions: MHL performed most of the experiments and organized data; JC contributed reagents and experimental materials; YSY and YQW were responsible for animal breeding and analyzed some data; YZ provided human cord blood; GQC revised the manuscript; and YH designed the experiments and wrote the paper.
Acknowledgments: we thank Professors Cheng-Cheng Zhang (University of Texas Southwestern Medical Center, USA) and Jun-ke Zheng (Shanghai Jiao Tong University School of Medicine, China) for kindly providing the MLL-AF9 plasmid and Professor Stephen
J. Elledge (Howard Hughes Medical Institute, USA) for the pINDUCER20.
Funding: this work was supported by a grant from the National Natural Science Foundation (81572290, HY).
References
1. Ling Y, Zhang Z, Zhang H, Huang Z. Protein kinase inhibitors as therapeutic drugs in AML: advances and challenges. Curr Pharm Des. 2017;23(29):4303-4310.
2. De Kouchkovsky I, Abdul-Hay M. Acute myeloid leukemia: a com- prehensive review and 2016 update. Blood Cancer J. 2016; 6(7):e441.
3. Arriazu E, Pippa R, Odero MD. Protein phosphatase 2A as a thera-
peutic target in acute myeloid leukemia. Front Oncol. 2016; 6:78.
4.Pippa R, Dominguez A, Malumbres R, et al. MYC-dependent recruitment of RUNX1 and GATA2 on the SET oncogene promoter enhances PP2A inactivation in acute myeloid leukemia. Oncotarget.
2017;8(33):53989-54003.
5. Lucas CM, Scott LJ, Carmell N, et al. CIP2A- and SETBP1-mediated
PP2A inhibition reveals AKT S473 phosphorylation to be a new bio- marker in AML. Blood Adv. 2018;2(9):964-968.
6. Yang Y, Huang Q, Lu Y, Li X, Huang S. Reactivating PP2A by FTY720 as a novel therapy for AML with C-KIT tyrosine kinase domain mutation. J Cell Biochem. 2012;113(4):1314-1322.
7.Fan L, Liu MH, Guo M, et al. FAM122A, a new endogenous inhibitor of protein phosphatase 2A. Oncotarget. 2016;7(39):63887- 63900.
8. Fan F, Zhao J, Liu Y, et al. Identifying the SUMO1 modification of FAM122A leading to the degradation of PP2A-Calpha by ubiquitin- proteasome system. Biochem Biophys Res Commun. 2018;500(3):676-681.
9. Zhou Y, Shi WY, He W, et al. FAM122A supports the growth of hepatocellular carcinoma cells and its deletion enhances doxoru- bicin-induced cytotoxicity. Exp Cell Res. 2020; 387(1):111714.
10. Krivtsov AV, Twomey D, Feng Z, et al. Transformation from com- mitted progenitor to leukaemia stem cell initiated by MLL-AF9. Nature. 2006;442(7104):818-822.
11. Dang CV. MYC, metabolism, cell growth, and tumorigenesis. Cold Spring Harb Perspect Med. 2013;3(8):a014217.
12. Lin SS, Bassik MC, Suh H, et al. PP2A regulates BCL-2 phosphory- lation and proteasome-mediated degradation at the endoplasmic reticulum. J Biol Chem. 2006;281(32):23003-23012.
13. Shamas-Din A, Brahmbhatt H, Leber B, Andrews DW. BH3-only proteins: orchestrators of apoptosis. Biochim Biophys Acta. 2011; 1813(4):508-520.
14.Hoffman B, Amanullah A, Shafarenko M, Liebermann DA. The proto-oncogene c-myc in hematopoietic development and leuke- mogenesis. Oncogene. 2002;21(21):3414-3421.
15.Noguchi K, Kitanaka C, Yamana H, Kokubu A, Mochizuki T, Kuchino Y. Regulation of c-Myc through phosphorylation at Ser-62 and Ser-71 by c-Jun N-terminal kinase. J Biol Chem. 1999; 274(46):32580-32587.
haematologica | 2021; 106(3)
907